Humacyte Inc (HUMA)vsNovartis AG ADR (NVS)
HUMA
Humacyte Inc
$0.57
+0.09%
HEALTHCARE · Cap: $165.73M
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2672837% more annual revenue ($56.69B vs $2.12M). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
HUMA
Avoid24
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+59.9%
Fair Value
$2.52
Current Price
$0.57
$1.95 discount
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 34.9% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -839.6% — below average capital efficiency
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : HUMA
The strongest argument for HUMA centers on Revenue Growth. Revenue growth of 34.9% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : HUMA
The primary concerns for HUMA are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 2.12 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
HUMA profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
HUMA carries more volatility with a beta of 2.47 — expect wider price swings.
HUMA is growing revenue faster at 34.9% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 24/100), backed by strong 22.5% margins. HUMA offers better value entry with a 59.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Humacyte Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Humacyte Inc (HUMA) is a groundbreaking biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels (HAVs). These innovative, off-the-shelf products are designed to meet pressing needs in vascular reconstruction and chronic disease management, improving patient outcomes and potentially reducing healthcare expenses. Leveraging its advanced technology platform, Humacyte is strategically positioned to drive innovation in transplantation and tissue engineering, thereby cementing its status as a transformative leader within the rapidly evolving landscape of medical therapies.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?